atrioventricular block |
Disease ID | 889 |
---|---|
Disease | atrioventricular block |
Manually Symptom | (Waiting for update.) |
Text Mined Symptom | UMLS | Name | Sentences' Count(Total Symptoms:3) |
Manually Genotype(Total Text Mining Genotypes:0) |
---|
(Waiting for update.) |
All Snps(Total Genotypes:3) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
snpId | pubmedId | geneId | geneSymbol | diseaseId | sourceId | sentence | score | Year | geneSymbol_dbSNP | CHROMOSOME | POS | REF | ALT |
rs120074189 | 20487114 | 3784 | KCNQ1 | umls:C0004245 | BeFree | This case is the first report of fetal 2:1 AV block with KCNQ1 mutation (T587M) and unmasked maternal QT prolongation in the postpartum period. | 0.002909916 | 2010 | KCNQ1 | 11 | 2778003 | C | T |
rs120074192 | 17467630 | 3784 | KCNQ1 | umls:C0004245 | BeFree | Human KCNQ1 S140G mutation is associated with atrioventricular blocks. | 0.002909916 | 2007 | KCNQ1 | 11 | 2527959 | A | G |
rs121913003 | 14991347 | 1674 | DES | umls:C0004245 | BeFree | We have previously characterized a de novo desmin R406W mutation in a patient of European origin with early onset muscle weakness in the lower extremities and atrioventricular conduction block requiring a permanent pacemaker. | 0.001357209 | 2004 | DES | 2 | 219421532 | C | T |
GWASdb Annotation(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
GWASdb Snp Trait(Total Genotypes:0) | |
---|---|
(Waiting for update.) |
Mapped by lexical matching(Total Items:0) |
---|
(Waiting for update.) |
Mapped by homologous gene(Total Items:0) |
---|
(Waiting for update.) |
Chemical(Total Drugs:51) | |||||||||
---|---|---|---|---|---|---|---|---|---|
CUI | ChemicalName | ChemicalID | CasRN | DiseaseName | DiseaseID | DirectEvidence | PubMedIDs | ||
C0004245 | adenosine triphosphate | D000255 | 56-65-5 | atrioventricular block | MESH:D054537 | marker/mechanism | 12381087 | ||
C0004245 | amitriptyline | D000639 | 50-48-6 | atrioventricular block | MESH:D054537 | marker/mechanism | 11089775 | ||
C0004245 | arsenic trioxide | C006632 | 1327-53-3 | atrioventricular block | MESH:D054537 | marker/mechanism | 10392399 | ||
C0004245 | atenolol | D001262 | 29122-68-7 | atrioventricular block | MESH:D054537 | marker/mechanism | 11229299 | ||
C0004245 | atropine | D001285 | 51-55-8 | atrioventricular block | MESH:D054537 | marker/mechanism | 2778956 | ||
C0004245 | atropine | D001285 | 51-55-8 | atrioventricular block | MESH:D054537 | therapeutic | 17711430 | ||
C0004245 | bupivacaine | D002045 | 2180-92-9 | atrioventricular block | MESH:D054537 | marker/mechanism | 18282259 | ||
C0004245 | caffeine | D002110 | 1958/8/2 | atrioventricular block | MESH:D054537 | marker/mechanism | 10337936 | ||
C0004245 | carbachol | D002217 | - | atrioventricular block | MESH:D054537 | marker/mechanism | 17277016 | ||
C0004245 | carbamazepine | D002220 | 298-46-4 | atrioventricular block | MESH:D054537 | marker/mechanism | 1148068 | ||
C0004245 | carteolol | D002354 | 51781-06-7 | atrioventricular block | MESH:D054537 | marker/mechanism | 12571398 | ||
C0004245 | cladribine | D017338 | 4291-63-8 | atrioventricular block | MESH:D054537 | marker/mechanism | 15561348 | ||
C0004245 | chloroquine | D002738 | 1954/5/7 | atrioventricular block | MESH:D054537 | marker/mechanism | 10381062 | ||
C0004245 | chlorpromazine | D002746 | 50-53-3 | atrioventricular block | MESH:D054537 | marker/mechanism | 1011369 | ||
C0004245 | cimetidine | D002927 | 51481-61-9 | atrioventricular block | MESH:D054537 | marker/mechanism | 2880057 | ||
C0004245 | cisapride | D020117 | 81098-60-4 | atrioventricular block | MESH:D054537 | marker/mechanism | 12595600 | ||
C0004245 | clonidine | D003000 | 4205-90-7 | atrioventricular block | MESH:D054537 | marker/mechanism | 3341873 | ||
C0004245 | cyclophosphamide | D003520 | 50-18-0 | atrioventricular block | MESH:D054537 | marker/mechanism | 17223814 | ||
C0004245 | dapsone | D003622 | 80-08-0 | atrioventricular block | MESH:D054537 | marker/mechanism | 19583683 | ||
C0004245 | diatrizoate | D003973 | 117-96-4 | atrioventricular block | MESH:D054537 | marker/mechanism | 3057857 | ||
C0004245 | digoxin | D004077 | 20830-75-5 | atrioventricular block | MESH:D054537 | marker/mechanism | 15334025 | ||
C0004245 | diltiazem | D004110 | 42399-41-7 | atrioventricular block | MESH:D054537 | marker/mechanism | 15234417 | ||
C0004245 | disopyramide | D004206 | 3737/9/5 | atrioventricular block | MESH:D054537 | marker/mechanism | 3970790 | ||
C0004245 | doxapram | D004315 | 309-29-5 | atrioventricular block | MESH:D054537 | marker/mechanism | 9672531 | ||
C0004245 | enflurane | D004737 | 13838-16-9 | atrioventricular block | MESH:D054537 | marker/mechanism | 3605739 | ||
C0004245 | epirubicin | D015251 | 56420-45-2 | atrioventricular block | MESH:D054537 | marker/mechanism | 17223814 | ||
C0004245 | erythromycin | D004917 | 114-07-8 | atrioventricular block | MESH:D054537 | marker/mechanism | 11724091 | ||
C0004245 | etomidate | D005045 | 33125-97-2 | atrioventricular block | MESH:D054537 | marker/mechanism | 18210663 | ||
C0004245 | fluorouracil | D005472 | 51-21-8 | atrioventricular block | MESH:D054537 | marker/mechanism | 8253323 | ||
C0004245 | fosphenytoin | C043114 | 93390-81-9 | atrioventricular block | MESH:D054537 | marker/mechanism | 16434340 | ||
C0004245 | imipramine | D007099 | 50-49-7 | atrioventricular block | MESH:D054537 | marker/mechanism | 1119616 | ||
C0004245 | labetalol | D007741 | 36894-69-6 | atrioventricular block | MESH:D054537 | marker/mechanism | 6476508 | ||
C0004245 | lidocaine | D008012 | 137-58-6 | atrioventricular block | MESH:D054537 | marker/mechanism | 18282259 | ||
C0004245 | mefloquine | D015767 | 53230-10-7 | atrioventricular block | MESH:D054537 | marker/mechanism | 20058779 | ||
C0004245 | metoprolol | D008790 | 37350-58-6 | atrioventricular block | MESH:D054537 | marker/mechanism | 18452693 | ||
C0004245 | morphine | D009020 | 57-27-2 | atrioventricular block | MESH:D054537 | marker/mechanism | 2446361 | ||
C0004245 | nicotine | D009538 | - | atrioventricular block | MESH:D054537 | marker/mechanism | 1259687 | ||
C0004245 | octreotide | D015282 | 83150-76-9 | atrioventricular block | MESH:D054537 | marker/mechanism | 14742361 | ||
C0004245 | omeprazole | D009853 | 73590-58-6 | atrioventricular block | MESH:D054537 | marker/mechanism | 12773066 | ||
C0004245 | paclitaxel | D017239 | - | atrioventricular block | MESH:D054537 | marker/mechanism | 17223814 | ||
C0004245 | pentobarbital | D010424 | 76-74-4 | atrioventricular block | MESH:D054537 | marker/mechanism | 3590213 | ||
C0004245 | phenylpropanolamine | D010665 | 14838-15-4 | atrioventricular block | MESH:D054537 | marker/mechanism | 3989943 | ||
C0004245 | phenytoin | D010672 | 57-41-0 | atrioventricular block | MESH:D054537 | marker/mechanism | 10407528 | ||
C0004245 | pilocarpine | D010862 | 92-13-7 | atrioventricular block | MESH:D054537 | marker/mechanism | 3785930 | ||
C0004245 | propranolol | D011433 | 525-66-6 | atrioventricular block | MESH:D054537 | marker/mechanism | 1879988 | ||
C0004245 | propranolol | D011433 | 525-66-6 | atrioventricular block | MESH:D054537 | therapeutic | 2444941 | ||
C0004245 | quinine | D011803 | 130-95-0 | atrioventricular block | MESH:D054537 | marker/mechanism | 3800084 | ||
C0004245 | sotalol | D013015 | 3930-20-9 | atrioventricular block | MESH:D054537 | marker/mechanism | 7162978 | ||
C0004245 | thalidomide | D013792 | 50-35-1 | atrioventricular block | MESH:D054537 | marker/mechanism | 16773277 | ||
C0004245 | timolol | D013999 | 26839-75-8 | atrioventricular block | MESH:D054537 | marker/mechanism | 10439680 | ||
C0004245 | tretinoin | D014212 | 302-79-4 | atrioventricular block | MESH:D054537 | marker/mechanism | 16447716 |
FDA approved drug and dosage information(Total Drugs:4) | ||||||||
---|---|---|---|---|---|---|---|---|
DiseaseID | Drug_name | active_ingredients | strength | Dosage Form/Route | Marketing Status | TE code | RLD | RS |
MESH:D054537 | prilosec | omeprazole | 20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | CAPSULE, DELAYED REL PELLETS;ORAL | Discontinued | None | Yes | No |
MESH:D054537 | prilosec | omeprazole | 20MG Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons | CAPSULE, DELAYED REL PELLETS;ORAL | Discontinued | None | Yes | No |
MESH:D054537 | omeprazole | omeprazole | 20MG | TABLET, DELAYED RELEASE;ORAL | Over-the-counter | None | Yes | Yes |
MESH:D054537 | omeprazole | omeprazole | 20MG | TABLET, DELAYED RELEASE;ORAL | Over-the-counter | None | Yes | Yes |
FDA labeling changes(Total Drugs:4) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DiseaseID | Pediatric_Labeling_Date | Trade_Name | Generic_Name_or_Proper_Name | Indications Studied | Label Changes Summary | Product Labeling | BPCA(B) | PREA(P) | BPCA(B) and PREA(P) | Pediatric Rule (R) | Sponsor | Pediatric Exclusivity Granted Date | NNPS |
MESH:D054537 | 12/7/2002 | prilosec | omeprazole | Gastroesophageal reflux and erosive esophagitis | Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile | Labeling | B | - | - | - | AstraZeneca | - | FALSE' |
MESH:D054537 | 03/20/2008 | prilosec | omeprazole | Maintenance healing of erosive esophagitis | Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form | Labeling | - | - | B, P | - | AstraZeneca | 1/5/2001 | FALSE' |
MESH:D054537 | 12/7/2002 | prilosec | omeprazole | Gastroesophageal reflux and erosive esophagitis | Safety and effectiveness established in pediatric patients 2-16 years of age Information on dose, PK parameters, exposure/response and AE profile | Labeling | B | - | - | - | AstraZeneca | - | FALSE' |
MESH:D054537 | 03/20/2008 | prilosec | omeprazole | Maintenance healing of erosive esophagitis | Efficacy was extrapolated from adults and older children to 1 to 2 year olds and supported with an open-label trial Unique adverse reactions in pediatric patients included increased respiratory system adverse events and fever. Safety and effectiveness in children less than 1 year of age have not been established Dosing and administration information provided for patients 1 year and older weighing at least 5 kg. New dosage form | Labeling | - | - | B, P | - | AstraZeneca | 1/5/2001 | FALSE' |